Unlabelled: The aim of this prospective study is to assess the effect of non indicated supplementation with Materna during normal pregnancy on some parameters of the neonate and the process of delivery. The material includes 98 women who had been taking Materna during the pregnancy and 27 cases without any medications. The criteria for inclusion are: normally progressing clinically and paraclinically pregnancy and delivery after completing 37th w.g. (95% confident interval 39.0-40.5).
Result: Most of the pregnant women take Materna for 3 to 5 months (95% CI) during pregnancy. The supplementation with Materna lead to increase of the BIP from the control group of 94.4 mm to 96.5; the occipitofrontal circumference from 33.9 to 35.1 and the high of the neonate from 50.2 to 51.1 respectively. The impression of the obstetricians engage in the study is that the scull bones are more solid and the molding of the head after the delivery is very small or even missing.
Conclusion: Unjustified supplementation of normal pregnancy with multivitamins and multiminerals lead to increase in the occipitofrontal circumference and to the decrease of the molding capacity of the fetal head wherefore the labor prolongs and the rate of CS and the operative vaginal deliveries increase.
Download full-text PDF |
Source |
---|
Obstet Gynecol
July 2024
Departments of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, and University of South Alabama at Mobile, Mobile, Alabama, University of North Carolina at Chapel Hill, Chapel Hill, and Duke University, Durham, North Carolina, University of Pennsylvania and Drexel University College of Medicine, Philadelphia, and Magee Women's Hospital and University of Pittsburgh, Pittsburgh, Pennsylvania, University of Texas at Houston and the Division of Maternal-Fetal Medicine, Baylor College of Medicine and Texas Children's Hospital, Houston, and University of Texas Medical Branch, Galveston, Texas, Columbia University and Weill Cornell University, New York, and New York Presbyterian Queens Hospital, Flushing, New York, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, Indiana University, Indianapolis, Indiana, University of Utah and Intermountain Healthcare, Salt Lake City, Utah, UnityPoint Health-Meriter Hospital/Marshfield Clinic, Madison, Wisconsin, Washington University in St. Louis, St. Louis, Missouri, University of Mississippi Medical Center, Jackson, Mississippi, The Ohio State University, Columbus, Ohio, Rutgers University-Robert Wood Johnson Medical School, New Brunswick, New Jersey, Medical College of Wisconsin, Milwaukee, Wisconsin, Yale University, New Haven, Connecticut, University of Colorado, Aurora, and Denver Health, Denver, Colorado, Emory University, Atlanta, Georgia.
Objective: To evaluate maternal and neonatal outcomes by type of antihypertensive used in participants of the CHAP (Chronic Hypertension in Pregnancy) trial.
Methods: We conducted a planned secondary analysis of CHAP, an open-label, multicenter, randomized trial of antihypertensive treatment compared with standard care (no treatment unless severe hypertension developed) in pregnant patients with mild chronic hypertension (blood pressure 140-159/90-104 mm Hg before 20 weeks of gestation) and singleton pregnancies. We performed three comparisons based on medications prescribed at enrollment: labetalol compared with standard care, nifedipine compared with standard care, and labetalol compared with nifedipine.
Obstet Gynecol
July 2024
Departments of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, and University of South Alabama at Mobile, Mobile, Alabama, University of North Carolina at Chapel Hill, Chapel Hill, and Duke University, Durham, North Carolina, University of Pennsylvania and Drexel University College of Medicine, Philadelphia, St. Luke's University Health Network, Bethlehem, Magee Women's Hospital and University of Pittsburgh, Pittsburgh, and Lehigh Valley Health Network, Allentown, Pennsylvania, University of Texas at Houston and Baylor College of Medicine and Texas Children's Hospital, Houston, and University of Texas Medical Branch, Galveston, Texas, Columbia University, New York, Winthrop University Hospital, Long Island, and New York Presbyterian Queens Hospital, Flushing, New York, University of Oklahoma, Oklahoma City, Oklahoma, MetroHealth System, Cleveland, The Ohio State University, Columbus, and Wright State University, Fairborn, Ohio, Indiana University, Indianapolis, Indiana, University of Utah Health, Salt Lake City, Utah, Christiana Care Health Services, Newark, Delaware, UnityPoint Health-Meriter Hospital/Marshfield Clinic, Madison, and Medical College of Wisconsin, Milwaukee, Wisconsin, Washington University in St. Louis, St. Louis, Missouri, University of Mississippi Medical Center, Jackson, Mississippi, Yale University, New Haven, Connecticut, University of Colorado, Aurora, and Denver Health Hospital, Denver, Colorado, Emory University, Atlanta, Georgia, University of California, San Francisco, San Francisco, and Stanford University, Stanford, California, Arrowhead Regional Medical Center/Beaumont Hospital, Detroit, Michigan, Virtua Health, Voorhees, New Jersey, Oregon Health & Science University, Portland, Oregon, University of Arkansas for Medical Sciences, Little Rock, Arkansas, University of Tennessee Health Science Center, Memphis, and Vanderbilt University Medical Center, Nashville, Tennessee, Tulane University, New Orleans, Louisiana, University of Kansas Medical Center, Kansas City, Kansas, and Medical University of South Carolina, Charleston, South Carolina; the Center for Women's Reproductive Health, the Department of Biostatistics, and the Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama; Penn State College of Medicine, Hershey, Pennsylvania; Intermountain Health, Salt Lake City, Utah; Ochsner Baptist Medical Center, New Orleans, Louisiana; St. Peters University Hospital and the Department of Obstetrics, Gynecology and Reproductive Health, New Jersey Medical School, Newark, and the Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers University-Robert Wood Johnson Medical School, New Brunswick, New Jersey; Weill Cornell University, New York, New York; Zuckerberg San Francisco General Hospital, San Francisco, California; TriHealth, Cincinnati Children's Hospital, Cincinnati, Ohio; the Division of Cardiovascular Sciences, NHLBI, Bethesda, Maryland; and the Department of Women's Health, University of Texas at Austin, Austin, Texas.
Objective: To estimate the association between mean arterial pressure during pregnancy and neonatal outcomes in participants with chronic hypertension using data from the CHAP (Chronic Hypertension and Pregnancy) trial.
Methods: A secondary analysis of the CHAP trial, an open-label, multicenter randomized trial of antihypertensive treatment in pregnancy, was conducted. The CHAP trial enrolled participants with mild chronic hypertension (blood pressure [BP] 140-159/90-104 mm Hg) and singleton pregnancies less than 23 weeks of gestation, randomizing them to active treatment (maintained on antihypertensive therapy with a goal BP below 140/90 mm Hg) or standard treatment (control; antihypertensives withheld unless BP reached 160 mm Hg systolic BP or higher or 105 mm Hg diastolic BP or higher).
Rev Bras Ginecol Obstet
April 2023
Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Unlabelled: Supplementation with folic acid (FA) during gestation has been recommended by medical society all over the world, but some studies have shown that intake of high folic acid diet may unleash damages to the descendants.
Objectives: Describing the effects of maternal supplementation with FA during gestation on offspring's kidney at late life stages.
Data Source: It is a systematic review by which were consulted the following databases: Medline, through Pubmed, Lilacs, and SciELO.
Bol Med Hosp Infant Mex
December 2022
Centro Médico ABC, Campus Santa Fe, Mexico City, Mexico.
As health professionals, we have memorized that "newborns can lose up to 10% of their birth weight during the first week of life and should regain it by two weeks of age". However, this statement, which appears so accurate, comes from studies conducted in the 1960s, when medical knowledge and how newborns were fed were utterly different from what it is today. Currently, multiple factors contribute to the percentage of weight loss at birth and the rate at which this weight is regained.
View Article and Find Full Text PDFJ Nutr Sci
June 2022
The Generation R Study Group, Erasmus University Medical Center, Rotterdam, The Netherlands.
We studied ethnic differences in terms of iron status during pregnancy between Dutch women and other ethnicities and explore to what extent these differences can be explained by environmental factors. This cross-sectional population-based study (2002-2006) was embedded in the Generation R study and included a total of 4737 pregnant women from seven ethnic groups (Dutch, Turkish, Moroccan, Cape Verdean, Surinamese-Hindustani, Surinamese-Creole and Antillean). Ethnicity was defined according to the Dutch classification of ethnic background.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!